BCMA

SEATTLE and SAN FRANCISCO and SAN JOSE, Calif. and NANJING, China and SUZHOU, China and SHANGHAI, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as…

Encouraging clinical activity in higher dose cohorts with 63% ORR and 88% DCR reported in 2150 µg/week cohort with 8 disease evaluable patients with relapsed/refractory multiple myeloma Tolerable safety profile with cytokine release…

STAMFORD, Conn., Aug. 30, 2021 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer,…

Three TriTAC clinical programs (HPN424, HPN536 and HPN328) have shown tumor size reductions or stable disease, and meaningful treatment durationAll four clinical programs demonstrate half-life extension, target engagement and T cell…

New York, NY, May 07, 2021 (GLOBE NEWSWIRE) -- Facts and Factors have published a new research report titled “B-Cell Maturation Antigen (BCMA) Targeted Therapies Market by Product Type (CAR-T cell, Antibody Drug Conjugates, and…